{"created":"2021-12-03T01:40:55.411381+00:00","id":2001663,"links":{},"metadata":{"_buckets":{"deposit":"7ca9d147-d519-4a51-8145-6857ae1aaf86"},"_deposit":{"created_by":17,"id":"2001663","owners":[17],"pid":{"revision_id":0,"type":"depid","value":"2001663"},"status":"published"},"_oai":{"id":"oai:nagoya.repo.nii.ac.jp:02001663","sets":["499:508:509:1638493189962"]},"author_link":[],"item_1615768549627":{"attribute_name":"出版タイプ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_9_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2021-11","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"4","bibliographicPageEnd":"840","bibliographicPageStart":"827","bibliographicVolumeNumber":"83","bibliographic_titles":[{"bibliographic_title":"Nagoya Journal of Medical Science","bibliographic_titleLang":"en"}]}]},"item_9_description_4":{"attribute_name":"内容記述","attribute_value_mlt":[{"subitem_description":"Tregs infiltrate tumors and inhibit antitumor immunity. KW-0761 (Mogamulizumab) is a humanized anti-CCR4 monoclonal antibody that could eliminate activated Tregs with high immunosuppressive activity that express CCR4. In this phase Ib trial, KW-0761 was used as a cancer immunotherapeutic reagent to deplete Tregs in patients with advanced or recurrent solid CCR4-negative tumors. Thirty-nine patients with solid cancer were treated with KW-0761 at a dose of 0.1 or 1.0 mg/kg. The safety, clinical responses, and effects of Treg depletion were analyzed. Any grade and grade 3–4 treatment-related adverse events (AEs) were observed in 36 (92%) and 14 (36%) out of 39 patients, respectively. All treatment-related AEs were manageable. One and 5 patients achieved a partial response and stable disease, respectively, during treatment and were long survivors. The efficient depletion of Treg in peripheral blood was confirmed in both cohorts. Therefore, the administration of KW-0761 was safe, resulting in the depletion of Tregs in peripheral blood and potential immune responses in patients with solid cancer. The combined use of KW-0761 to deplete Tregs and other immunotherapies is a promising approach to augment immune responses.","subitem_description_language":"en","subitem_description_type":"Abstract"}]},"item_9_identifier_registration":{"attribute_name":"ID登録","attribute_value_mlt":[{"subitem_identifier_reg_text":"10.18999/nagjms.83.4.827","subitem_identifier_reg_type":"JaLC"}]},"item_9_publisher_32":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Nagoya University Graduate School of Medicine, School of Medicine","subitem_publisher_language":"en"}]},"item_9_relation_43":{"attribute_name":"関連情報","attribute_value_mlt":[{"subitem_relation_type":"isVersionOf","subitem_relation_type_id":{"subitem_relation_type_id_text":"https://www.med.nagoya-u.ac.jp/medlib/nagoya_j_med_sci/834.html","subitem_relation_type_select":"URI"}}]},"item_9_rights_12":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International","subitem_rights_language":"en","subitem_rights_resource":"http://creativecommons.org/licenses/by-nc-nd/4.0/"}]},"item_9_source_id_7":{"attribute_name":"収録物識別子","attribute_value_mlt":[{"subitem_source_identifier":"0027-7622","subitem_source_identifier_type":"PISSN"},{"subitem_source_identifier":"2186-3326","subitem_source_identifier_type":"EISSN"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"open access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_abf2"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Saito, Takuro","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Kurose, Koji","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Kojima, Takashi","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Funakoshi, Takeru","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Sato, Eiichi","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Nishikawa, Hiroyoshi","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Nakajima, Jun","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Seto, Yasuyuki","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Kakimi, Kazuhiro","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Iida, Shinsuke","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Doki, Yuichiro","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Oka, Mikio","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Ueda, Ryuzo","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Wada, Hisashi","creatorNameLang":"en"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_access","date":[{"dateType":"Available","dateValue":"2021-12-03"}],"displaytype":"detail","filename":"15-2_Saito.pdf","filesize":[{"value":"548 KB"}],"format":"application/pdf","licensetype":"license_5","mimetype":"application/pdf","url":{"objectType":"fulltext","url":"https://nagoya.repo.nii.ac.jp/record/2001663/files/15-2_Saito.pdf"},"version_id":"5d109d55-9349-48a2-af88-fcbf107e1397"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"solid cancer patients","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"mogamulizumab","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"regulatory T cells","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"clinical trial","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"CCR4","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Phase Ib study on the humanized anti-CCR4 antibody, KW-0761, in advanced solid tumors","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Phase Ib study on the humanized anti-CCR4 antibody, KW-0761, in advanced solid tumors","subitem_title_language":"en"}]},"item_type_id":"40001","owner":"17","path":["1638493189962"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2021-12-03"},"publish_date":"2021-12-03","publish_status":"0","recid":"2001663","relation_version_is_last":true,"title":["Phase Ib study on the humanized anti-CCR4 antibody, KW-0761, in advanced solid tumors"],"weko_creator_id":"17","weko_shared_id":-1},"updated":"2023-11-16T01:56:44.349481+00:00"}